Development of targeting nanotherapeutics against bladder cancer
Development of targeting nanotherapeutics against bladder cancer
批准号:
9275369
负责人:
CHONG-XIAN PAN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-10-01 至 2017-09-30
关键词:
BCG VaccineBindingBladderBlood CellsCancer ControlCancer cell lineCanis familiarisCellsChronic CystitisClinicalCompanionsDataDevelopmentDoctor of MedicineDoctor of PhilosophyDrug Delivery SystemsDrug KineticsDrug MonitoringFibroblastsFormulationFundingGoalsHomingHumanImmunocompromised HostK-Series Research Career ProgramsKnowledgeLigandsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of urinary bladderMentorsMusNamesOrganPaclitaxelPatientsPeptidesPharmaceutical PreparationsPharmacology and ToxicologyPilot ProjectsSiteSpecimenStructureSurfaceSystemTherapeuticTherapeutic AgentsTherapeutic EffectTimeToxic effectTreatment EfficacyTreatment outcomeTreatment-related toxicityUrothelial CellVascular Endothelial CellWorkXenograft procedurebiomaterial compatibilitycancer cellchemotherapeutic agentdensitydrug distributiondrug efficacyimaging agentimaging detectionimaging potentialimprovedin vivointravenous injectionnanotherapeuticnoveloutcome forecastpeptide analogpreclinical studytargeted deliverytumor xenograft
中文摘要
描述(由申请人提供):
该项目的目标是开发一种可以特异性靶向膀胱癌的纳米胶束药物递送系统。在VA职业发展奖-2(CDA-2,PI:Pan)的资助下,开发了一种名为PLZ 4的膀胱癌靶向配体。PLZ 4结合人和狗膀胱癌细胞系以及来自临床标本的癌细胞,这表明可以在患有自发性膀胱癌的狗中进行临床前研究。PLZ 4不与正常的尿路上皮细胞、发炎的膀胱细胞、血细胞、血管内皮细胞和成纤维细胞结合。最近,Kit Lam,MD,PhD(潘博士的VA CDA-2导师)开发了生物相容性和生物可降解的纳米胶束。 化学试剂和成像剂可以装载在纳米胶束内。当它们在表面上用PLZ 4修饰时,这些靶向纳米胶束与药物负载一起被递送到膀胱癌细胞中。靶向PLZ 4-纳米胶束优先集中在体内膀胱癌异种移植部位,与非靶向纳米胶束相比,可以显著延长存活期。在本项目中,我们将优化PLZ 4-纳米胶束的结构,以实现最大的药物负载和递送,并确定在携带从人类临床标本开发的膀胱癌异种移植物的小鼠中的体内靶向和药物分布。将在患有自发性膀胱癌的犬患者中进行初步研究,以获得初步毒性和疗效数据。
英文摘要
DESCRIPTION (provided by applicant):
The goal of this project is to develop a nanomicelle drug delivery system that can specifically target bladder cancer. With the funding of the VA Career Development Award-2 (CDA-2, PI: Pan), a bladder cancer-targeting ligand named PLZ4 was developed. PLZ4 binds to both human and dog bladder cancer cell lines and cancer cells from clinical specimens, suggesting that the pre-clinical studies can be performed in dogs with spontaneous bladder cancer. PLZ4 does not bind to normal urothelial cells, inflamed bladder cells, blood cells, vascular endothelial cells an fibroblasts. Recently, Kit Lam, MD, PhD, (Dr. Pan's VA CDA-2 mentor) developed biocompatible and biodegradable nanomicelles. Chemotherapeutic and imaging agents can be loaded inside the nanomicelles. When they are decorated with PLZ4 on surface, these targeting nanomicelles together with the drug load are delivered into bladder cancer cells. Targeting PLZ4-nanomicelles preferentially concentrate at the bladder cancer xenograft sites in vivo and can significantly prolong survival when compared to non-targeting nanomicelles. In this project, we will optimize the structure of the PLZ4-nanomicelles to achieve the maximal drug loading and delivery, and determine the in vivo targeting and drug distribution in mice carrying bladder cancer xenografts developed from human clinical specimens. A pilot study will be conducted in dog patients carrying spontaneous bladder cancer in order to obtain the preliminary toxicity and efficacy data.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1371/journal.pone.0105326
发表时间:
2014
期刊:
PloS one
影响因子:
3.7
作者:
[Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R]
通讯作者:
Liu R
BCCMA: Translational research to improve the care of advanced bladder cancer
-
批准号:10588312
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:CHONG-XIAN PAN
-
依托单位:
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
-
批准号:10426035
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:CHONG-XIAN PAN
-
依托单位:
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
-
批准号:10578717
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:CHONG-XIAN PAN
-
依托单位:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
-
批准号:10158416
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:CHONG-XIAN PAN
-
依托单位:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
-
批准号:9898243
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:CHONG-XIAN PAN
-
依托单位:
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
-
批准号:10085104
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:CHONG-XIAN PAN
-
依托单位:
Targeted-and timed-releasing nanotherapeutics against leukemia stem cells
-
批准号:10162055
-
项目类别:
-
资助金额:$10.88万
-
财政年份:2015
-
负责人:CHONG-XIAN PAN
-
依托单位:
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
-
批准号:9260776
-
项目类别:
-
资助金额:$35.91万
-
财政年份:2015
-
负责人:CHONG-XIAN PAN
-
依托单位:
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells
-
批准号:9454297
-
项目类别:
-
资助金额:$35.91万
-
财政年份:2015
-
负责人:CHONG-XIAN PAN
-
依托单位:
Development of targeting nanotherapeutics against bladder cancer
-
批准号:8442030
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:CHONG-XIAN PAN
-
依托单位:
Development of targeting nanotherapeutics against bladder cancer
-
批准号:8764627
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:CHONG-XIAN PAN
-
依托单位:
DEVELOP ASSAY TO QUANT PLAT-DNA ADDUCTS & PREDICT RESPONSE TO CHEMOTHERA
-
批准号:7977084
-
项目类别:
-
资助金额:$5.83万
-
财政年份:2009
-
负责人:CHONG-XIAN PAN
-
依托单位:
DEVELOP ASSAY TO QUANT PLAT-DNA ADDUCTS & PREDICT RESPONSE TO CHEMOTHERA
-
批准号:7724094
-
项目类别:
-
资助金额:$5.43万
-
财政年份:2008
-
负责人:CHONG-XIAN PAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: